Form 4: Incyte Director Julian Baker Receives Equity Compensation, Baker Bros. Entities Disclose Holdings

Julian C. Baker, a director of Incyte Corporation and representative of Baker Bros. entities, received 492 shares of Incyte common stock as quarterly director retainer fees, leading to updated beneficial ownership disclosures for associated funds and individuals.

Summary

• Julian C. Baker, a director of Incyte Corporation, received 492 shares of Incyte common stock on June 30, 2025.
• These shares were issued under Incyte's Amended and Restated 2010 Stock Incentive Plan in lieu of $33,000 in quarterly director retainer fees and are fully vested.
• The shares are indirectly owned by 667, L.P. and Baker Brothers Life Sciences, L.P. (the "Funds"), as Julian C. Baker serves on the board as their representative.
• Baker Bros. Advisors LP, as the investment adviser to the Funds, has complete and unlimited discretion and authority over the investment and voting power of these securities.
• Following this transaction, 667, L.P. is associated with 2,816,902 indirectly held shares, and Baker Brothers Life Sciences, L.P. with 28,187,581 indirectly held shares.
• Julian C. Baker directly holds 278,773 shares, and Felix J. Baker directly holds 281,190 shares.
• An additional 33,410 shares are indirectly held through FBB Associates, where Julian C. Baker and Felix J. Baker are sole partners.
• Julian C. Baker, Felix J. Baker, Baker Bros. Advisors (GP) LLC, and Baker Bros. Advisors LP disclaim beneficial ownership of the securities held by the Funds except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: The document is a routine Form 4 filing detailing director compensation in equity and associated beneficial ownership changes. It is neutral in sentiment as it reports a standard transaction without indicating significant positive or negative operational or financial news for the company. The alignment of director compensation with equity is generally viewed positively, but the filing itself is purely informational.

Positives

• Director compensation through equity aligns the interests of the director with shareholders.
• The shares received are fully vested, indicating immediate ownership and no future vesting conditions.

Future Outlook

The document is a transactional filing (Form 4) and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• Julian C. Baker serves on the Issuer's board of directors (the 'Board') as a representative of 667, L.P. ('667') and Baker Brothers Life Sciences, L.P. ('Life Sciences', and together with 667, the 'Funds') and their affiliates and control persons.
• Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
• Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities.

Industry Context

This Form 4 filing reflects routine director compensation in the form of equity, a common practice across industries, including biotechnology, to align director incentives with shareholder value. The significant indirect holdings by Baker Bros. entities underscore their continued substantial investment and influence within Incyte Corporation, a prominent player in the biotechnology sector.

Comparison to Industry Standards

• Equity compensation for directors is a standard practice in publicly traded companies, including those in the biotechnology and pharmaceutical sectors, such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals, to foster alignment with shareholder interests.
• The specific value of $33,000 for quarterly retainer fees converted to equity is within the typical range for non-executive director compensation at companies of Incyte's size and market capitalization.
• The structure of indirect ownership through investment funds (Baker Bros. Advisors) with disclaimers of direct beneficial ownership, except for pecuniary interest, is a common legal and reporting mechanism for large institutional investors with board representation.

Related Party Transactions

• Julian C. Baker, a director of Incyte Corporation, received 492 shares of common stock in lieu of quarterly director retainer fees. This is a transaction between the company and a related party (a director).
• The shares are indirectly held by funds (667, L.P. and Baker Brothers Life Sciences, L.P.) advised by Baker Bros. Advisors LP, whose managing members (Julian C. Baker and Felix J. Baker) are also reporting persons and have direct and indirect interests in Incyte.

Stakeholder Impact

• Shareholders: The issuance of shares as director compensation slightly dilutes existing shareholders but aligns director incentives with shareholder value. The disclosure provides transparency regarding significant institutional ownership.
• Management: The transaction reflects standard compensation practices for board members, supporting corporate governance structures.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• Continued service of Julian C. Baker on the Incyte Corporation Board of Directors.
• Future quarterly director retainer fees may continue to be issued in common stock under the Stock Incentive Plan.

Key Dates

Keywords

Incyte Corporation, INCY, SEC Form 4, Beneficial Ownership, Director Compensation, Equity Grant, Stock Incentive Plan, Baker Bros. Advisors, Julian C. Baker, Felix J. Baker, Institutional Investor, Biotechnology, Pharmaceuticals